Last week, Galmed Pharmaceuticals (NASDAQ:GLMD) shares climbed as high as $9.90 per share this week, up approximately 7% on the day after the company released updated phase IIb results for Aramchol, the company’s treatment for NASH (non-alcoholic steatohepatitis). Galmed reported […]
If you are a stock picker or have ever dabbled in the market, you may understand that there is actually a magic bullet to achieving investing success: it’s called research. You need to put in the time to find information that […]